LONDON (dpa-AFX) - Oxford Biomedica plc (OXB.L) said that it has signed a new three year master services & development agreement with AstraZeneca UK Ltd which would facilitate potential future
AstraZeneca's COVID-19 vaccine, Vaxzevria (ChAdOx1-S [Recombinant]), has been granted approval in the European Union (EU) by the European Medicine Agency (EMA) as a third dose booster in adults. Healthcare professionals can now use Vaxzevria as a third dose booster in patients previously given a primary vaccine .
Researchers have identified novel biomarkers for dementia-causing diseases that may assist in identifying risk factors and development of new therapies.